Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / May / Treasures of the Deep
Discovery & Development Drug Discovery Research News

Treasures of the Deep

Could aquatic bacteria hold the keys to bolstering our drug pipelines?

By Maryam Mahdi 05/13/2019 0 min read Quick Read (pre 2022)

Share

On a rocky shore in northern Portugal, researchers from the University of Porto have been busy collecting heaps of brown seaweed. Their purpose? To explore the bioactivity of the Actinobacteria found within it. 

Actinobacteria, a phylum of Gram-positive bacteria, are ubiquitous in soil, freshwater and marine environments, and are clinically used for many antibiotics, as well as anticancer and anti-inflammatory agents. In fact, more than half of the 20,000 microbe-derived drug candidates in development stem from the terrestrial species of the bacteria. But aquatic Actinobacteria haven’t received as much attention.

“The diversity of the natural world is unparalleled. The adversities presented by their environments forces living organisms to adapt mechanisms of defense, which often results in the production of compounds with useful bioactivities,” explains Maria de Fátima Carvalho, Principal Investigator at the Interdisciplinary Centre of Marine and Environmental Research of the University of Porto. 

Carvalho is interested in isolating Actinobacteria from diverse sources, and so rather than focusing on the bench, she went to the coastline in pursuit of new therapeutic molecules (1). The team investigated cultivable Actinobacteria associated with Laminaria ochroleuca seaweed and were able to recover 90 isolates. Forty-five of the strains identified were capable of inhibiting the growth of Candida albicans (an opportunistic yeast that causes candidiasis) and Staphylococcus aureus, and a further 28 displayed inhibitory effects on breast carcinoma and neuroblastoma cell lines. The team also discovered two strains that produced bioactive compounds not previously featured in common databases of natural products, and are now investigating them with increased scrutiny to determine if they are indeed novel chemical entities.

“Up to 90 percent of drugs are rejected in preclinical drug screening,” says Carvalho. “Until now, no one had characterized the Actinobacteria in L. ochroleuca. Our findings are an exciting step in the right direction. The more drugs candidates available – and the more strains of Actinobacteria we discover to feed drug development channels – the better!”

Carvalho and her team intend to further explore Portugal’s waters in search of other species of seaweed – and new communities of Actinobacteria.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. MF Carvalho et al., “Actinobacteria Isolated From Laminaria ochroleuca: A Source of New Bioactive Compounds”. Frontiers in Microbiology 10:683. (2019).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.